![]() This conflict’s geopolitical repercussions could have a significant effect on global markets, especially the Fluoro Enzymatic Assays market. The Global Fluoro Enzymatic Assays Report also examines the war between Russia and Ukraine’s overall effects on the keyword market. In-depth information about important market participants, their market shares, and their strategies for remaining competitive in the sector are also covered in the study. Readers can learn in-depth information about various market segments and their potential for growth thanks to this segmentation. The Global Fluoro Enzymatic Assays Industry Report offers a thorough overview of the market based on a variety of factors, including product type, application, end-user industry, geography, and market segmentation and coverage. In Brief This Week is a selection of n ews items that may be of interest to our readers but had not previously appeared on added new report titled “2023-2031 Fluoro Enzymatic Assays Industry Key Insights and Forecasts ” to its research database. Following the quarter, the credit facility was extended for an additional two months and is due on June 11. The agreement was for a short-term senior secured demand credit facility in the aggregate amount of C$7.5 million, bearing interest at 15 percent per year for two months. The company noted that during the quarter, the New York State Department of Health granted conditional approval to its diagnostic testing partner, KSL Diagnostics, for SQI Diagnostics' Exact COVID-19 Antibody Test.įurther, to finance the acquisition of the Precision Biomonitoring assets, SQI entered into a credit agreement with Pivot Financial, an arm's length third party, and certain insiders of the company. Its Q2 R&D expenses rose 33 percent year over year to C$2.8 million from C$2.1 million, mainly due to higher headcount, while its SG&A expenses rose 56 percent to C$2.5 million from C$1.6 million, primarily due to one-time costs for the Precision Biomonitoring acquisition.Īt the end of Q2, SQI had cash and cash equivalents of C$1.5 million. The firm posted a fiscal Q2 gross profit of C$3.0 million compared to a gross profit of C$300,000 in the year-ago quarter. The company attributed the revenue growth to the acquisition of the Precision Biomonitoring COVID-19 testing business during the quarter for C$6.8 million in cash and stock, a deal that was announced in January. For the quarter ended March 31, the Toronto-based firm totaled revenues of C$5.6 million (US$4.4 million) compared to revenues of C$300,000 in Q2 2021. SQI Diagnostics this week posted a more than 18-fold year-over-year increase in second quarter revenues for fiscal year 2022. The company has been developing an AI-driven, epigenetics-based clinical test for cardiovascular disease called Epi+Gen CHD that assesses the risk for the onset of new coronary heart disease. Agilent employs more than 800 people at Little Falls.Ĭardio Diagnostics said this week that it has moved its headquarters to Chicago, where it will be based at Portal Innovations in Fulton Market. The investment will support the redesign, demolition, construction, and outfitting of current laboratories. The company plans to invest more than $7 million to upgrade the functionality of the Little Falls R&D and applications development labs at a three-level, 354,000-square-foot site. Data from the trial may allow the company to file for FDA clearance of the panel later this year.Īgilent Technologies said this week that it plans to expand its Little Falls office and lab campus in Wilmington, Delaware, in response to growing worldwide demand for analytical laboratory consumables. The firm said a US clinical trial for the panel is continuing and is expected to be completed this year. T2 Biosystems said in a document filed with the US Securities and Exchange Commission this week that the US Food and Drug Administration has denied the company's application for breakthrough device designation for its T2Biothreat Panel. The QuidelOrtho board is composed of eight former Quidel board members and four former Ortho board members. Former Quidel stockholders received one share of QuidelOrtho common stock for each share of Quidel common stock. Under the terms of the agreement governing the transaction, former Ortho Clinical Diagnostics shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. The combined firm generated more than $3.5 billion in revenues in 2021. ![]() The company will be headquartered in San Diego, has approximately 6,000 employees, and will trade on the Nasdaq under the ticker symbol QDEL. NEW YORK – Quidel announced this week the completion of its combination with Ortho Clinical Diagnostics, creating QuidelOrtho. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |